ATE216226T1 - Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden - Google Patents

Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden

Info

Publication number
ATE216226T1
ATE216226T1 AT97200415T AT97200415T ATE216226T1 AT E216226 T1 ATE216226 T1 AT E216226T1 AT 97200415 T AT97200415 T AT 97200415T AT 97200415 T AT97200415 T AT 97200415T AT E216226 T1 ATE216226 T1 AT E216226T1
Authority
AT
Austria
Prior art keywords
tissue damage
sorbitol dehydrogenase
dehydrogenase inhibitors
associated tissue
reduce ischemia
Prior art date
Application number
AT97200415T
Other languages
English (en)
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE216226T1 publication Critical patent/ATE216226T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT97200415T 1996-02-29 1997-02-13 Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden ATE216226T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270896P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
ATE216226T1 true ATE216226T1 (de) 2002-05-15

Family

ID=21756305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97200415T ATE216226T1 (de) 1996-02-29 1997-02-13 Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden

Country Status (15)

Country Link
US (1) US5932581A (de)
EP (1) EP0791355B1 (de)
JP (1) JPH09316004A (de)
KR (1) KR100219972B1 (de)
CN (1) CN1165000A (de)
AT (1) ATE216226T1 (de)
AU (1) AU714038B2 (de)
CA (1) CA2198536C (de)
DE (1) DE69711965T2 (de)
DK (1) DK0791355T3 (de)
ES (1) ES2174176T3 (de)
IL (1) IL120271A (de)
MY (1) MY118982A (de)
PT (1) PT791355E (de)
ZA (1) ZA971715B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020005653A (ko) * 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CN104346404B (zh) * 2013-08-08 2018-05-18 华为技术有限公司 一种访问数据的方法、设备及系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE4025387A1 (de) 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
WO1994007867A1 (en) 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
CA2198536C (en) 2000-06-20
JPH09316004A (ja) 1997-12-09
AU714038B2 (en) 1999-12-16
CA2198536A1 (en) 1997-08-29
MX9701527A (es) 1998-06-30
AU1500997A (en) 1997-09-04
DK0791355T3 (da) 2002-06-17
IL120271A (en) 2001-06-14
EP0791355B1 (de) 2002-04-17
DE69711965D1 (de) 2002-05-23
KR970061257A (ko) 1997-09-12
CN1165000A (zh) 1997-11-19
US5932581A (en) 1999-08-03
EP0791355A1 (de) 1997-08-27
ZA971715B (en) 1998-08-27
ES2174176T3 (es) 2002-11-01
MY118982A (en) 2005-02-28
KR100219972B1 (ko) 1999-09-01
IL120271A0 (en) 1997-06-10
PT791355E (pt) 2002-08-30
DE69711965T2 (de) 2003-01-23

Similar Documents

Publication Publication Date Title
FI894748A7 (fi) Uusia peptidaasi-inhibiittoreita
EA200101166A1 (ru) Ингибиторы металлопротеаз
FI971412L (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
ATE216239T1 (de) Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden
DE69824183D1 (de) N-alkanoylphenylalaninderivate
FI961976A7 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
NZ335981A (en) Ketobenzamides as calpain inhibitors
ES2090244T3 (es) Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
AR004348A1 (es) Reduccion del crecimiento del cabello
ATE199545T1 (de) Inhibitoren retroviraler proteasen
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
TR200101120T2 (tr) Serin proteaz inhibitörü
PL349511A1 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
DE69711965D1 (de) Verwendung von Sorbitol-Dehydrogenase-Inhibitoren zum Reduzieren von Ischämie-assozierten Gewebeschäden
SE0301883D0 (sv) New use II
AR004330A1 (es) Uso de inhibidores de colinesterasa en el tratamiento de xerostomia
CO5021190A1 (es) Agentes terapeuticos
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
ES2173158T3 (es) Reduccion del tejido adiposo utilizando colagenasa
ATE296345T1 (de) Verwendung eines kristallwachstumsinhibitors zur verminderung der abreibung von geweben
NO912517D0 (no) Fremgangsmaate for forlengelse av brukstiden for belegginhibitorer injisert i en formasjon.
FI970807L (fi) Tiosemikarbatsidien käyttö lahonestoaineina
KR940018986U (ko) 질감염 치료용 템포

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee